European Commission approves Inaqovi(decitabine and cedazuridine) to treat acute myeloid leukemia
Otsuka Pharmaceutical announced that European regulatory authorities have approved Inaqovi, a fixed-dose combination of decitabine and cedazuridine originated by Astex Pharmaceuticals, for the treatment of acute myeloid leukemia (AML).
The European Commission has approved the drug, previously known as ASTX 727, as a monotherapy for adult patients with newly diagnosed AML who are ineligible for standard induction chemotherapy. The approval makes Inaqovi the first and only oral hypomethylating agent indicated for this patient population in the region.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.